BRPI0814931A2 - Composto com atividade contra hcv, sua composição e seu uso - Google Patents

Composto com atividade contra hcv, sua composição e seu uso

Info

Publication number
BRPI0814931A2
BRPI0814931A2 BRPI0814931-3A2A BRPI0814931A BRPI0814931A2 BR PI0814931 A2 BRPI0814931 A2 BR PI0814931A2 BR PI0814931 A BRPI0814931 A BR PI0814931A BR PI0814931 A2 BRPI0814931 A2 BR PI0814931A2
Authority
BR
Brazil
Prior art keywords
composite
composition
hcv activity
hcv
activity
Prior art date
Application number
BRPI0814931-3A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Scott W Martins
Carl P Bergstrom
Robert G Gentles
Kap-Sun Yeung
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0814931A2 publication Critical patent/BRPI0814931A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0814931-3A2A 2007-08-09 2008-08-01 Composto com atividade contra hcv, sua composição e seu uso BRPI0814931A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US4994408P 2008-05-02 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C
PCT/US2008/071881 WO2009029384A2 (en) 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
BRPI0814931A2 true BRPI0814931A2 (pt) 2015-02-03

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814931-3A2A BRPI0814931A2 (pt) 2007-08-09 2008-08-01 Composto com atividade contra hcv, sua composição e seu uso

Country Status (18)

Country Link
US (1) US7652004B2 (https=)
EP (1) EP2183252B1 (https=)
JP (1) JP5465670B2 (https=)
KR (1) KR20100066492A (https=)
CN (1) CN101821267B (https=)
AR (1) AR067897A1 (https=)
AU (1) AU2008293845B2 (https=)
BR (1) BRPI0814931A2 (https=)
CA (1) CA2695781A1 (https=)
CL (1) CL2008002353A1 (https=)
CO (1) CO6251359A2 (https=)
EA (1) EA015978B1 (https=)
MX (1) MX2010001416A (https=)
NZ (1) NZ583149A (https=)
PE (1) PE20090618A1 (https=)
TW (1) TW200906418A (https=)
WO (1) WO2009029384A2 (https=)
ZA (1) ZA201000923B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
KR20100108341A (ko) * 2007-11-20 2010-10-06 브리스톨-마이어스 스큅 컴퍼니 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
KR20100124848A (ko) 2008-03-27 2010-11-29 브리스톨-마이어스 스큅 컴퍼니 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2012517468A (ja) * 2009-02-11 2012-08-02 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎治療のための化合物
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
CH706864B1 (de) 2011-06-22 2016-03-31 Central Glass Co Ltd Verfahren zur Herstellung einer Pyrazol-Verbindung.
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20090250T1 (hr) 2004-02-24 2009-06-30 Japan Tobacco Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1807403A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP5205370B2 (ja) * 2006-05-25 2013-06-05 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
US7652004B2 (en) 2010-01-26
AR067897A1 (es) 2009-10-28
AU2008293845B2 (en) 2013-02-14
AU2008293845A1 (en) 2009-03-05
MX2010001416A (es) 2010-03-01
EA015978B1 (ru) 2012-01-30
CO6251359A2 (es) 2011-02-21
US20090074715A1 (en) 2009-03-19
WO2009029384A2 (en) 2009-03-05
JP2010535787A (ja) 2010-11-25
ZA201000923B (en) 2011-04-28
EP2183252A2 (en) 2010-05-12
EA201000277A1 (ru) 2010-06-30
PE20090618A1 (es) 2009-05-16
KR20100066492A (ko) 2010-06-17
WO2009029384A3 (en) 2009-05-28
CN101821267B (zh) 2013-07-10
EP2183252B1 (en) 2015-01-14
JP5465670B2 (ja) 2014-04-09
CL2008002353A1 (es) 2008-10-24
NZ583149A (en) 2011-07-29
CA2695781A1 (en) 2009-03-05
TW200906418A (en) 2009-02-16
CN101821267A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
BRPI0814931A2 (pt) Composto com atividade contra hcv, sua composição e seu uso
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI0718192A2 (pt) Corantes dispersos, sua preparação e seu uso.
BRPI1011521A2 (pt) Composto de hidrazida e uso do mesmo no controle de pragas.
BRPI1010957A2 (pt) variantes de celulase com expressão, atividade e/ou estabilidade aprimorada e uso das mesmas.
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
BRPI0821276A2 (pt) Produto, e, uso do produto
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0918789A2 (pt) variantes de beta-glicosidase tendo atividade melhorada, e uso das mesmas
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0806589A2 (pt) Catalisador, sua preparação e uso.
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0813263A2 (pt) Oxazolidinonas substituídas e seu uso
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0808798A2 (pt) Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas
BRPI0818641A2 (pt) Rótulo, e, uso do rótulo
BRPI0921441A2 (pt) liga de cobre-estanho, material composto e uso
BRPI0812766A2 (pt) 4-cloro-4-alcóxi-1,1,1-triflúor-2-butanonas, preparação das mesmas e uso das mesmas no preparo de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0907053A2 (pt) Poliisobutenoamina, composição combustível, e, uso de poliisobutenoaminas
BRPI0908786A2 (pt) Composição de material com estrutura porosa, métodos de preparação e usos correspondentes
BRPI0810323A2 (pt) "combinação de ácido pirrolidona 5-carboxílico, uso do ácido pirrolidona 5-carboxílico, composição e seu uso"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.